Models of HIV-1 persistence in the CD4 + T cell compartment: Past, present and future

Current HIV Research

Volumn 9, Issue 8, 2011, Pages 579-587

  Tyagi, Mudit ^a   Romerio, Fabio ^b  

^a GEORGE MASON UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

HIV 1; In vitro models; Latency

Indexed keywords

ANTIRETROVIRUS AGENT; INTERLEUKIN 7; PROTEIN BCL 2;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL COMPARTMENTALIZATION; CELL METABOLISM; COMPARATIVE STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IN VITRO STUDY; MOLECULAR MODEL; NONHUMAN; PERSISTENT INFECTION; PRIMARY CELL CULTURE; T LYMPHOCYTE ACTIVATION; VIRUS ASSEMBLY; VIRUS LATENCY; VIRUS TRANSCRIPTION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; DISEASE RESERVOIRS; HIV INFECTIONS; HIV-1; HUMANS; MODELS, BIOLOGICAL; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84856448350     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016211798998754     Document Type: Article

References (91)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338(13): 853-60.
2. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194(1): 11-9.
3. Richman DD, Margolis DM, Delaney M, et al. The challenge of finding a cure for HIV infection. Science 2009; 323(5919): 1304-7.
4. Moore JP, Klasse PJ, Dolan MJ, et al. AIDS/HIV. A STEP into darkness or light? Science 2008; 320(5877): 753-5.
5. Watkins DI, Burton DR, Kallas EG, et al. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008; 14(6): 617-21.
6. Bowman MC, Archin NM, Margolis DM. Pharmaceutical approaches to eradication of persistent HIV infection. Expert Rev Mol Med 2009; 11: p. e6.
7. Piatak M Jr., Saag MS, Yang LC et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993; 259(5102): 1749-54.
8. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337(11): 725-33.
9. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337(11): 734-9.
10. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997; 276(5314): 960-4.
11. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271(5255): 1582-6.
12. Murray JM, Emery S, Kelleher AD, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007; 21(17): 2315-21.
13. Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41(10): 4531-6.
14. Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999; 282(17): 1627-32.
15. Hermankova M, Ray SC, Ruff C, et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA 2001; 286(2): 196-207.
16. Lee PK, Kieffer TL, Siliciano RF, et al. HIV-1 viral load blips are of limited clinical significance. J Antimicrob Chemother 2006; 57(5): 803-5.
17. Phillips AN, Ledergerber B, Horban A, et al. Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. AIDS 2004; 18(13): 1795-804.
18. Ortiz GM, Wellons M, Brancato J, et al. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A 2001; 98(23): 13288-93.
19. Dinoso JB, Kim SY, Wiegand AM, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2009; 106(23): 9403-8.
20. Ramratnam B, Ribeiro R, He T, et al. Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr 2004; 35(1): 33-7.
21. Kieffer TL, Finucane MM, Nettles RE, et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 2004; 189(8): 1452-65.
22. Iglesias-Ussel MD, Romerio F. HIV reservoirs: the new frontier. AIDS Rev 2011; 13(1): 13-29.
23. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002; 53: 557-93.
24. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15(8): 893-900.
25. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387(6629): 183-8.
26. Siliciano JD, Siliciano RF. Latency and viral persistence in HIV-1 infection. J Clin Invest 2000; 106(7): 823-5.
27. Harper ME, Marselle LM, Gallo RC et al. Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization. Proc Natl Acad Sci U S A 1986; 83(3): 772-6.
28. Schnittman SM, Psallidopoulos MC, Lane HC, et al. The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science 1989; 245(4915): 305-8.
29. Psallidopoulos MC, Schnittman SM, Thompson LM, et al. Integrated proviral human immunodeficiency virus type 1 is present in CD4+ peripheral blood lymphocytes in healthy seropositive individuals. J Virol 1989; 63(11): 4626-31.
30. Chun TW, Finzi D, Margolick J, et al. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1995; 1(12): 1284-90.
31. Trono D, Van Lint C, Rouzioux C, et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010; 329(5988): 174-80.
32. Choudhary SK, Margolis DM. Curing HIV: Pharmacologic approaches to target HIV-1 latency. Annu Rev Pharmacol Toxicol 2011; 51: 397-418.
33. Han Y, Wind-Rotolo M, Yang HC, et al. Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol 2007; 5(2): 95-106.
34. Chun TW, Engel D, Mizell SB, et al. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med 1998; 188(1): 83-91.
35. Moriuchi H, Moriuchi M, Fauci AS. Induction of HIV-1 replication by allogeneic stimulation. J Immunol 1999; 162(12): 7543-8.
36. Korin YD, Brooks DG, Brown S, et al. Effects of prostratin on Tcell activation and human immunodeficiency virus latency. J Virol 2002; 76(16): 8118-23.
37. Scripture-Adams DD, Brooks DG, Korin YD, et al. Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol 2002; 76(24): 13077-82.
38. Brooks DG, Hamer DH, Arlen PA, et al. Molecular characterization, reactivation, and depletion of latent HIV. Immunity 2003; 19(3): 413-23.
39. Shen A, Yang HC, Zhou Y, et al. Novel pathway for induction of latent virus from resting CD4(+) T cells in the simian immunodeficiency virus/macaque model of human immunodeficiency virus type 1 latency. J Virol 2007; 81(4): 1660-70.
40. Folks TM, Clouse KA, Justement J, et al. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A 1989; 86(7): 2365-8.
41. Antoni BA, Rabson AB, Kinter A, et al. NF-kappa B-dependent and-independent pathways of HIV activation in a chronically infected T cell line. Virology 1994; 202(2): 684-94.
42. Folks TM, Justement J, Kinter A, et al. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 1987; 238: 800-2.
43. Pearson R, Kim YK, Hokello J, et al. Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency. J Virol 2008; 82(24): 12291-303.
44. Kutsch O, Benveniste EN, Shaw GM, et al. Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J Virol 2002; 76: 8776-86.
45. Folks T, Powell DM, Lightfoote MM, et al. Induction of HTLVIII/ LAV from a nonvirus-producing T-cell line: implications for latency. Science 1986; 231(4738): 600-2.
46. Verdin E. DNase I-hypersensitive sites are associated with both long terminal repeats and with the intragenic enhances of integrated human immunodeficiency virus type 1. J Virol 1991; 65: 6790-9.
47. Verdin E, Paras PJ, Van Lint C. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 1993; 12; 3249-59.
48. Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 2003; 22: 1868-77.
49. Bisgrove D, Lewinski M, Bushman F, et al. Molecular mechanisms of HIV-1 proviral latency. Expert Rev Anti Infect Ther 2005; 3(5): 805-14.
50. Hakre S, Chavez L, Shirakawa, et al. Epigenetic regulation of HIV latency. Curr Opin HIV AIDS 2011; 6(1): 19-24.
51. Chavez L, Kauder S, Verdin E. In vivo, in vitro, and in silico analysis of methylation of the HIV-1 provirus. Methods 2011; 53(1): 47-53.
52. Ott M, Dorr A, Hetzer-Egger C, et al. Tat acetylation: a regulatory switch between early and late phases in HIV transcription elongation. Novartis Found Symp 2004; 259: 182-93.
53. Lenasi T, Contreras X, Peterlin BM. Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe 2008; 4(2): 123-33.
54. Han Y, Lassen K, Monie D, et al. Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol 2004; 78(12): 6122-33.
55. Lewinski MK, Bisgrove D, Shinn P, et al. Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J Virol 2005; 79(11): 6610-9.
56. Shan L, Yang HC, Rabi SA, et al. Influence of Host Gene Transcription Level and Orientation on HIV-1 Latency in a Primary-Cell Model. J Virol 2011 85(11): 5384-93.
57. Yukl S, Pillai S, Li P, et al. Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity. Virology 2009; 387(1): 98-108.
58. Emiliani S, Fischle W, Ott M, et al. Mutations in the Tat gene are responsible for human immunodeficiency virust type 1 postintegration latency in the U1 cell line. J Virol 1998; 72: 1666-70.
59. Reza SM, Rosetti M, Mathews MB, et al. Differential activation of Tat variants in mitogen-stimulated cells: implications for HIV-1 postintegration latency. Virology 2003; 310: 141-56.
60. Corish P, Tyler-Smith C. Attenuation of green fluorescent protein half-life in mammalian cells. Protein Eng 1999; 12: 1035-40.
61. Kim YK, Bourgeois CF, Pearson R, et al. Recruitment of TFIIH to the HIV LTR is a rate-limiting step in the emergence of HIV from latency. EMBO J 2006; 25(15): 3596-604.
62. Tyagi M, Karn J. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J 2007; 26(24): 4985-95.
63. Emiliani S, Van Lint C, Fischle W, et al. A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency. Proc Natl Acad Sci U S A 1996; 93(13): 6377-81.
64. Gondois-Rey F, Biancotto A, Pion M, et al. Production of HIV-1 by resting memory T lymphocytes. AIDS 2001; 15(15): 1931-40.
65. Zack JA, Arrigo SJ, Weitsman SR, et al. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990; 61: 213-22.
66. Pierson TC, Zhou Y, Kieffer TL, et al. Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol 2002; 76: 8518-31.
67. Siliciano JD, Siliciano RF. A long-term latent reservoir for HIV-1: discovery and clinical implications. J Antimicrob Chemother 2004; 54(1): 6-9.
68. Swiggard WJ, Baytop C, Yu JJ, et al. Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J Virol 2005; 79(22): 14179-88.
69. O'Doherty U, Swiggard WJ, Malim MH. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol 2000; 74(21): 10074-80.
70. Guo J, Wang W, Yu D, et al. Spinoculation triggers dynamic actin and cofilin activity facilitating HIV-1 infection of transformed and resting CD4 T cells. J Virol 2011.
71. Saleh S, Solomon A, Wightman F, et al. CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood 2007; 110(13): 4161-4.
72. Cameron PU, Saleh S, Sallmann G, et al. Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton. Proc Natl Acad Sci U S A 2010; 107(39): 16934-9.
73. Burke B, Brown HJ, Marsden MD, et al. Primary cell model for activation-inducible human immunodeficiency virus. J Virol 2007; 81(14): 7424-34.
74. Marini A, Harper JM, Romerio F. An in vitro system to model the establishment and reactivation of HIV-1 latency. J Immunol 2008; 181(11): 7713-20.
75. Bradley LM, Haynes L, Swain SL. IL-7: maintaining T-cell memory and achieving homeostasis. Trends Immunol 2005; 26(3): 172-6.
76. Khaled AR, Durum SK. Death and Baxes: mechanisms of lymphotrophic cytokines. Immunol Rev 2003; 193: 48-57.
77. Li J, Huston G, Swain SL. IL-7 promotes the transition of CD4 effectors to persistent memory cells. J Exp Med 2003; 198(12): 1807-15.
78. Wang FX, Xu Y, Sullivan J, et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005; 115(1): 128-37.
79. Scripture-Adams DD, Brooks DG, Korin YD, et al. Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol 2002; 76: 13077-82.
80. Bosque A, Planelles V. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 2009; 113(1): 58-65.
81. Messi M, Giacchetto I, Nagata K, et al. Memory and flexibility of cytokine gene expression as separable properties of human T(H)1 and T(H)2 lymphocytes. Nat Immunol 2003; 4(1): 78-86.
82. Kauder SE, Bosque A, Lindqvist A, et al. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 2009; 5(6): e1000495.
83. Burnett JC, Lim KI, Calafi A, et al. Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol 2010; 84(12): 5958-74.
84. Yang HC, Xing S, Shan L, et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 2009.
85. Xing S, Bullen CK, Shroff NS, et al. Disulfiram Reactivates Latent HIV-1 in a Bcl-2-Transduced Primary CD4+ T Cell Model without Inducing Global T Cell Activation. J Virol 2011; 85(12): 6060-4.
86. Sahu GK, Lee K, Ji J, et al. A novel in vitro system to generate and study latently HIV-infected long-lived normal CD4+ Tlymphocytes. Virology 2006; 355(2): 127-37.
87. Tyagi M, Pearson RJ, Karn J. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J Virol 2010; 84(13): 6425-37.
88. Refaeli Y, Van Parijs L, London CA, et al. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 1998; 8(5): 615-23.
89. Ahmadzadeh M, Hussain SF, Farber DL. Effector CD4 T cells are biochemically distinct from the memory subset: evidence for longterm persistence of effectors in vivo. J Immunol 1999; 163(6): 3053-63.
90. Berger EA, Moss B, Pastan I. Reconsidering targeted toxins to eliminate HIV infection: you gotta have HAART. Proc Natl Acad Sci U S A 1998; 95(20): 11511-3.
91. Fabre-Mersseman V, Dutrieux J, Louise A, et al. CD4 recent thymic emigrants are infected by HIV in vivo, implication for pathogenesis. AIDS 2011. 25(9): 1153-62.